Patents by Inventor Rita Steeves

Rita Steeves has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080171856
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: October 29, 2007
    Publication date: July 17, 2008
    Applicant: IMMUNOGEN, INC.
    Inventors: Rita STEEVES, Robert Lutz, Ravi Chari, Hongsheng Xie, Yelena Kovtun
  • Publication number: 20080171865
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: October 29, 2007
    Publication date: July 17, 2008
    Applicant: IMMUNOGEN, INC.
    Inventors: Rita Steeves, Robert Lutz, Ravi Chari, Hongsheng Xie, Yelena Kovtun
  • Publication number: 20080145374
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: October 29, 2007
    Publication date: June 19, 2008
    Applicant: IMMUNOGEN, INC.
    Inventors: Rita STEEVES, Robert Lutz, Ravi Chari, Hongsheng Xie, Yelena Kovtun
  • Publication number: 20080114153
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: October 29, 2007
    Publication date: May 15, 2008
    Applicant: IMMUNOGEN. INC.
    Inventors: Rita Steeves, Robert Lutz, Ravi Chari, Hongsheng Xie, Yelena Kovtun
  • Publication number: 20060233814
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Application
    Filed: April 14, 2006
    Publication date: October 19, 2006
    Inventors: Viktor Goldmakher, Robert Lutz, Ravi Chari, Yelena Kovtun, John Lambert, Rita Steeves, Hans Erickson
  • Publication number: 20060127407
    Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
    Type: Application
    Filed: November 30, 2005
    Publication date: June 15, 2006
    Inventors: Qiming Chen, Mohit Trikha, Robert Lutz, Rita Steeves, Godfrey Amphlett
  • Publication number: 20050169933
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: October 8, 2004
    Publication date: August 4, 2005
    Inventors: Rita Steeves, Robert Lutz, Ravi Chari, Hongsheng Xie, Yelena Kovtun